The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).
 
Shahneen Sandhu
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst); Skyline Diagnostics (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Shalini Subramaniam
Research Funding - AAA/Endocyte/Novartis (Inst); Astellas Pharma (Inst)
Travel, Accommodations, Expenses - MSD
 
Hayley Thomas
No Relationships to Disclose
 
Thean Tan
No Relationships to Disclose
 
Jeffrey Goh
Stock and Other Ownership Interests - ICON Cancer Care
Honoraria - MSD Oncology
Consulting or Advisory Role - Abbvie; Eisai; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Janssen; MSD Oncology
Travel, Accommodations, Expenses - Bayer
 
Nattakorn Dhiantravan
Research Funding - Advancell (Inst); Novartis (Inst)
 
Andrew Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Merck Sharp & Dohme
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods; Use of Darovasertib for Neoadjuvant treatment ocular Melanoma
 
Ian Kirkwood
Stock and Other Ownership Interests - CSL Limited; Sonic Healthcare
 
Sze Ting Lee
No Relationships to Disclose
 
Craig Gedye
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Icon Cancer Care; Merck Sharp & Dohme (Inst); Novotech; SERVIER (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Andrew Nguyen
No Relationships to Disclose
 
David Pattison
No Relationships to Disclose
 
Ramin Alipour
No Relationships to Disclose
 
Roslyn Francis
Employment - AIQ Solutions (I)
Stock and Other Ownership Interests - AIQ Solutions (I)
Consulting or Advisory Role - AIQ Solutions (Inst)
Research Funding - AIQ Solutions (Inst)
 
Michael Hofman
Consulting or Advisory Role - Janssen; MSD; Novartis (Inst)
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Debiopharm Group (Inst); Novartis
 
Andrew Martin
No Relationships to Disclose
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Louise Emmett
Consulting or Advisory Role - Advancell; Astellas Pharma; Clarity Pharmaceuticals; Novartis
Speakers' Bureau - Astellas Pharma (Inst); Janssen Oncology; mundipharma; Novartis
Research Funding - Clarity Pharma (Inst); Novartis (Inst); PCF (Inst)
Travel, Accommodations, Expenses - Advancell
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose